Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Ionis Pharmaceuticals

Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong

Ionis Pharmaceuticals stock surged Monday after the company unveiled promising results for a drug that treats a rare genetic condition.

Investors Business Daily

Ionis Pharmaceuticals Stock Sees IBD RS Rating Climb To 79

Ionis Pharmaceuticals Stock Sees IBD RS Rating Climb To 79

Ionis Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test

Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test

Ionis stock tumbled Friday after partner AstraZeneca decided against sending their high cholesterol treatment into Phase 3 testing.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022

Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6 or PF-06760805 for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy. Pfizer shares traded in a…

Ionis Sacrifices A Breakout; Quarterly Miss Outweighs Intact Guide

Ionis Pharmaceuticals kept its 2022 outlook intact Tuesday despite a broad second-quarter miss. But IONS stock tumbled.

Investors Business Daily

Ionis Pharmaceuticals Stock Composite Rating Jumps To 96

The IBD SmartSelect Composite Rating for Ionis Pharmaceuticals increased from 94 to 96 Friday.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

Alnylam's 5th Drug Launches in July, Disrupting Commercial Landscape

Alnylam's 5th Drug Launches in July, Disrupting Commercial Landscape

A little competition can greatly benefit patients. Shareholders may have a more difficult path to navigate.

Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed

Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Ionis Pharmaceuticals (NASDAQ:IONS) reported Q1 sales of $142.00 million. Earnings fell to a loss of $65.17 million, resulting in a 129.01% decrease from last quarter.

What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals

What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals

Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings:

Recap: Ionis Pharmaceuticals Q1 Earnings

Recap: Ionis Pharmaceuticals Q1 Earnings

Ionis Pharmaceuticals (NASDAQ:IONS) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Expert Ratings For Ionis Pharmaceuticals

Expert Ratings For Ionis Pharmaceuticals

Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings:

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022

Get all your
news in one place.

100’s of premium titles.
One news app.

What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals

Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings within the last quarter:

BofA Downgrades Ionis After Vupanorsen Setback: Are There Upcoming Catalysts That Can Help The Stock?

Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced on Monday the discontinuation of the Vupanorsen clinical development program. Following this, there are no high-impact catalysts for the next 12 months that could unlock value, according to BofA Securities.

Investors Business Daily

Pfizer Backs Out Of Deal, But Former Partner Ionis Pares Its Losses

Pfizer backed out of a deal to co-develop an Ionis Pharmaceuticals heart-disease drug on Monday. But IONS stock pared its losses.

1

Organisations

European Commission

BofA Securities

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play